Pizzocaro G, Piva L, Faustini M, Nicolai N, Salvioni R, Pisani E, Maggioni A, Mandressi A, Dormia E, Minervini S
Istituto Nazionale Tumori, Milano.
Arch Ital Urol Androl. 1993 Apr;65(2):173-6.
Twenty-eight consecutive patients submitted to radical nephrectomy for Robson's stage II-III renal cell carcinoma underwent adjuvant recombinant a-2b interferon, 5 MUI s.c. 3 times a week, for 6 consecutive months. Home-feasibility of this therapy resulted easy. The most frequent acute (flu-like syndrome) and late (myalgia, fatigue, anorexia) side effects did not affect normal daily life of patients. Eight (28.5%) patients had WHO grade < or = 2 biochemical and hematological toxicity, that normalized after a reduction or a temporarily suspension of therapy. Twenty-seven patients were evaluable for response. Out of these, 7 (26%) relapsed after a 16 months median follow-up.
连续28例因罗布森II - III期肾细胞癌接受根治性肾切除术的患者接受了辅助性重组α-2b干扰素治疗，剂量为5百万国际单位，皮下注射，每周3次，连续6个月。这种治疗在家庭中实施很容易。最常见的急性（流感样综合征）和晚期（肌痛、疲劳、厌食）副作用并未影响患者的正常日常生活。8例（28.5%）患者出现世界卫生组织1级或2级生化和血液学毒性，在减少剂量或暂时中断治疗后恢复正常。27例患者可评估疗效。其中，中位随访16个月后，7例（26%）复发。
